GLAXOSMITHKLINE PHARMACEUTICALS
|
|
| BOM : 500660     NSE : GLAXO     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jun 22,2026 |
|
Price(EOD): ₹ 2,365.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 40,072.42 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | 7.5% | 1.9% | -30.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.5% | -1.5% | 9% |
| DIVIS LABORATORIES | 1.1% | -1.1% | 0.8% |
| TORRENT PHARMACEUTICALS | -0.2% | -0.3% | 35% |
| CIPLA | 3.1% | 1% | -11.3% |
| DR REDDYS LABORATORIES | 1.1% | -2.1% | -5.6% |
| MANKIND PHARMA | 7.7% | 0.9% | 2.1% |
| LUPIN | 2.7% | 2.4% | 17% |
| ZYDUS LIFESCIENCES | 0.6% | 4.7% | 10% |
FUNDAMENTAL ANALYSIS OF GLAXOSMITHKLINE PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLAXOSMITHKLINE PHARMACEUTICALS
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
38.68
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,035.98 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 17.55
P/B Calculated based on Book Value of Rs 2,283.12 Cr
[Latest Year - Mar2026 - Consolidated Results ] 10.49
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 3,821.67 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
13% 25% 23% |
SHARE PRICE MOMENTUM OF GLAXOSMITHKLINE PHARMACEUTICALS
GLAXOSMITHKLINE PHARMACEUTICALS vs SENSEX
DEBT OF GLAXOSMITHKLINE PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2026 2025 2024 Avg_3yrs |
0 0 0 - |
0 0 0 - |
|
[Last Annual Data : Mar2026]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GLAXOSMITHKLINE PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GLAXOSMITHKLINE PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-4.41% -5.5% -6.71% -6.01% |
2.15% 5.32% 4.05% 5.7% |
| QtrlyTrend |
0 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 400 MIDSMALLCAP INDEX | 2.5% | 4.3% | 4.9% |
| BSE HEALTHCARE | 2.3% | 1.2% | 9.6% |
| BSE QUALITY INDEX | 2.2% | 1.4% | 4% |
| BSE 150 MIDCAP INDEX | 2.2% | 3.1% | 5.7% |
| BSE 500 QUALITY 50 | 2.2% | 0.6% | NA |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 QUALITY 50 INDEX | 2.9% | 2.1% | 2.3% |
| NIFTY MIDSMALLCAP400 50:50 | 2.7% | 4.9% | NA |
| NIFTY 500 EQUAL WEIGHT | 2.6% | 5.4% | 4.3% |
| NIFTY MIDSMALLCAP 400 | 2.5% | 4.2% | 6.2% |
| NIFTY500 HEALTHCARE INDEX | 2.2% | 0.6% | NA |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS
Is GLAXOSMITHKLINE PHARMACEUTICALS good for long term investment?
As on Jun 22,2026, the Fundamentals of GLAXOSMITHKLINE PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of GLAXOSMITHKLINE PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLAXOSMITHKLINE PHARMACEUTICALS UnderValued or OverValued?
As on Jun 22,2026, GLAXOSMITHKLINE PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS ?
As on Jun 22,2026, the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS is Rs. 1,917.87 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,093.54
Fair Value [Median EV / Sales Model] : Rs. 1,887.34
Fair Value [Median Price / Sales Model] : Rs. 1,917.87
Estimated Median Fair Value of GLAXOSMITHKLINE PHARMACEUTICALS : Rs. 1,917.87
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.